I-GC203 iyindlela entsha yokwelapha i-TIL engeyona i-viral vector gene-modified TIL ethuthukiswe kusetshenziswa ipulatifomu yokukhulisa amaseli e-DeepTIL® e-Juncell Therapeutics kanye nepulatifomu yokuguqula amaseli e-NovaGMP®. I-DeepTIL® ivumela ama-TIL ukuba abe namandla ngokwanele kangangokuthi akukho nhlanganisela ye-IL-2 ezodingeka ngemva kokufakwa, futhi ukuqina kokwelashwa kwangaphambi kwesikhathi kungaba phansi. I-NovaGMP® iguqula amaseli e-T ngokusebenza kahle okuphezulu okufana ne-vector ye-Lentiviral ngendlela engabizi. I-GC203 yakhiwe nge-interleukin-7 ezihlanganisayo, engagcina ukuqina kwamaseli e-T enkumbulo, isebenze amaseli omzimba angaphakathi futhi igweme ubuthi besistimu.
Abacwaningi bahlole i-GC203 ezigulini ezitholakale zinomdlavuza wesibeletho ophindaphindayo, ngaphandle kokuhlanganiswa kokuphathwa kwe-IL-2 noma i-aggressive lymphodepletion. Inhloso yalolu cwaningo kwakuwukuthola ukuphepha nokusebenza kahle kwalokhu kwelashwa. Iziguli ezingu-20 zizonke zabhaliswa phakathi kuka-09/2021 no-01/2024 esivivinyweni se-single-center esivulekile, lapho iziguli ezingu-18 zahlolwa khona. Iziguli ezihlolwayo zazine-ECOG PS engu-1 (55.6%) noma ezingu-2 (44.4%) futhi zathola isilinganiso sezindlela zokwelapha ezi-5 zangaphambilini (ububanzi: 2-11). Iziguli ezingu-9 (50%) zazinezilonda ze-tumor ezintathu noma ngaphezulu. Usayizi wezilonda eziqondiwe wawungu-57 (ububanzi: 13-146) mm.
I-GC203 ibonise imiphumela ethembisayo ezigulini ezinomdlavuza wesibeletho ophindaphindayo noma osakazekile. Iphrofayili yokuphepha ithuthukiswe kakhulu uma iqhathaniswa nezindlela zokwelapha ze-TIL ezivamile, ngenxa yokwelashwa okuphansi kwangaphambi kokwelashwa kanye nokususwa kwenhlanganisela ye-IL-2. Iningi lezehlakalo ezimbi (ama-AE) kwakuyibanga loku-1 noma ibanga lesi-2 futhi zingancishiswa noma zelashwe ngokwelashwa okunezimpawu. Akukho sigameko sebanga lesi-5 esenzeka. Ngosuku lokugcina lwango-01/2024, izinga lokuphendula elihlosiwe ngumcwaningi (i-ORR) lalingu-33.3% (95% CI: 16.3 - 56.3), kufaka phakathi impendulo ephelele engu-11.1% (CR). Izinga lokulawula izifo (DCR) lalingu-83.3% (95% CI, 60.8 - 94.2). Futhi izinga lokusinda okujwayelekile (OS) lezinyanga ezingu-12 lalingu-68.8% (95% CI: 49.3 - 95.9). I-OS ephakathi yayingavuthiwe njengoba idatha inqunywa.
Ngo-2023, uNksz H wangeniswa esibhedlela ngo-2023 ngenxa yesisu.nobuhlungu besinqeNgemva kokuhlolwa, kwatholakala ukuthi ama-lymph node amaningi akhulisiwe e-retroperitoneum, e-groin, nakwezinye izindawo, okuqinisekisa ukutholakala kwakhe enomdlavuza we-serous ovarian wezinga eliphezulu. Ngakho-ke uNksz H wenziwa i-chemotherapy, ukuhlinzwa, i-immunotherapy, njll., kodwa umphumela wawungemuhle, futhi isimila empeleni saphinde savela.
Ngakho-ke, uNksz H wabamba iqhaza esivivinyweni sokwelashwa kweseli le-TIL i-GC203, kwathi ngemva kwenyanga eyodwa yokwelashwa nge-GC203, isimila sancipha ngo-37.3%.
Iziphetho: Ukufakwa kwe-GC203inokuphepha okwamukelekayo kanye nokusebenza kahle okukhulu ezigulini ezihlala zigula ezine-OC ezinokukhetha okulinganiselwe kokwelashwa.
Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.
Inombolo yocingo: 4008803716
Email：myimmnet@163.com
Izinkomba
1.https://www.juncell.com/academic-achievements
2.https://www.juncell.com/company-news-76
3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5552
4.http://myimm.net/mianyizhiliao/2037.html
Isikhathi sokuthunyelwe: Disemba 11-2024